PMC:7560789 / 3920-5234
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":631,"end":640},"obj":"Body_part"},{"id":"T6","span":{"begin":636,"end":640},"obj":"Body_part"},{"id":"T7","span":{"begin":997,"end":1001},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma63368"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma256135"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T21","span":{"begin":459,"end":463},"obj":"Disease"},{"id":"T22","span":{"begin":505,"end":507},"obj":"Disease"},{"id":"T24","span":{"begin":607,"end":618},"obj":"Disease"},{"id":"T25","span":{"begin":664,"end":680},"obj":"Disease"},{"id":"T26","span":{"begin":742,"end":754},"obj":"Disease"},{"id":"T27","span":{"begin":1014,"end":1018},"obj":"Disease"},{"id":"T28","span":{"begin":1021,"end":1058},"obj":"Disease"},{"id":"T29","span":{"begin":1041,"end":1058},"obj":"Disease"},{"id":"T30","span":{"begin":1060,"end":1062},"obj":"Disease"},{"id":"T32","span":{"begin":1065,"end":1082},"obj":"Disease"},{"id":"T33","span":{"begin":1109,"end":1122},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A23","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0016367"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0001475"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0021094"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A31","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0016367"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T30","span":{"begin":229,"end":231},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T31","span":{"begin":234,"end":236},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T32","span":{"begin":238,"end":240},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T33","span":{"begin":334,"end":336},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T34","span":{"begin":341,"end":344},"obj":"http://purl.obolibrary.org/obo/CLO_0053001"},{"id":"T35","span":{"begin":347,"end":350},"obj":"http://purl.obolibrary.org/obo/CLO_0054060"},{"id":"T36","span":{"begin":355,"end":358},"obj":"http://purl.obolibrary.org/obo/CLO_0053001"},{"id":"T37","span":{"begin":631,"end":640},"obj":"http://purl.obolibrary.org/obo/CL_0000034"},{"id":"T38","span":{"begin":733,"end":741},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T39","span":{"begin":733,"end":741},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"},{"id":"T40","span":{"begin":838,"end":840},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T41","span":{"begin":841,"end":843},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T54","span":{"begin":50,"end":53},"obj":"Chemical"},{"id":"T56","span":{"begin":67,"end":70},"obj":"Chemical"},{"id":"T58","span":{"begin":264,"end":266},"obj":"Chemical"},{"id":"T59","span":{"begin":324,"end":326},"obj":"Chemical"},{"id":"T61","span":{"begin":395,"end":398},"obj":"Chemical"},{"id":"T62","span":{"begin":505,"end":507},"obj":"Chemical"},{"id":"T63","span":{"begin":557,"end":571},"obj":"Chemical"},{"id":"T64","span":{"begin":801,"end":804},"obj":"Chemical"},{"id":"T65","span":{"begin":935,"end":937},"obj":"Chemical"},{"id":"T66","span":{"begin":987,"end":989},"obj":"Chemical"},{"id":"T67","span":{"begin":1060,"end":1062},"obj":"Chemical"},{"id":"T68","span":{"begin":1084,"end":1087},"obj":"Chemical"},{"id":"T70","span":{"begin":1124,"end":1127},"obj":"Chemical"},{"id":"T71","span":{"begin":1175,"end":1177},"obj":"Chemical"}],"attributes":[{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A55","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A57","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_74795"},{"id":"A60","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_90284"},{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_64198"},{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_141426"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_35371"},{"id":"A65","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A67","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_141426"},{"id":"A68","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A69","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_35371"},{"id":"A71","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_74795"},{"id":"A72","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_90284"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T25","span":{"begin":0,"end":8},"obj":"Sentence"},{"id":"T26","span":{"begin":10,"end":46},"obj":"Sentence"},{"id":"T27","span":{"begin":47,"end":102},"obj":"Sentence"},{"id":"T28","span":{"begin":103,"end":160},"obj":"Sentence"},{"id":"T29","span":{"begin":161,"end":209},"obj":"Sentence"},{"id":"T30","span":{"begin":210,"end":256},"obj":"Sentence"},{"id":"T31","span":{"begin":257,"end":316},"obj":"Sentence"},{"id":"T32","span":{"begin":317,"end":377},"obj":"Sentence"},{"id":"T33","span":{"begin":378,"end":458},"obj":"Sentence"},{"id":"T34","span":{"begin":459,"end":504},"obj":"Sentence"},{"id":"T35","span":{"begin":505,"end":548},"obj":"Sentence"},{"id":"T36","span":{"begin":549,"end":606},"obj":"Sentence"},{"id":"T37","span":{"begin":607,"end":630},"obj":"Sentence"},{"id":"T38","span":{"begin":631,"end":663},"obj":"Sentence"},{"id":"T39","span":{"begin":664,"end":732},"obj":"Sentence"},{"id":"T40","span":{"begin":733,"end":796},"obj":"Sentence"},{"id":"T41","span":{"begin":797,"end":844},"obj":"Sentence"},{"id":"T42","span":{"begin":845,"end":898},"obj":"Sentence"},{"id":"T43","span":{"begin":899,"end":1223},"obj":"Sentence"},{"id":"T44","span":{"begin":1224,"end":1301},"obj":"Sentence"},{"id":"T45","span":{"begin":1302,"end":1314},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}
LitCovid-PD-GlycoEpitope
{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T5","span":{"begin":378,"end":391},"obj":"GlycoEpitope"}],"attributes":[{"id":"A5","pred":"glyco_epitope_db_id","subj":"T5","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T21","span":{"begin":50,"end":53},"obj":"Phenotype"},{"id":"T22","span":{"begin":67,"end":70},"obj":"Phenotype"},{"id":"T23","span":{"begin":459,"end":463},"obj":"Phenotype"},{"id":"T24","span":{"begin":607,"end":618},"obj":"Phenotype"},{"id":"T25","span":{"begin":664,"end":680},"obj":"Phenotype"},{"id":"T26","span":{"begin":742,"end":754},"obj":"Phenotype"},{"id":"T27","span":{"begin":1014,"end":1018},"obj":"Phenotype"},{"id":"T28","span":{"begin":1021,"end":1058},"obj":"Phenotype"},{"id":"T29","span":{"begin":1065,"end":1082},"obj":"Phenotype"},{"id":"T30","span":{"begin":1084,"end":1087},"obj":"Phenotype"},{"id":"T31","span":{"begin":1090,"end":1122},"obj":"Phenotype"}],"attributes":[{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0001875"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0002721"},{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A29","pred":"hp_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"107","span":{"begin":85,"end":93},"obj":"Species"},{"id":"108","span":{"begin":459,"end":463},"obj":"Disease"},{"id":"109","span":{"begin":505,"end":507},"obj":"Disease"},{"id":"110","span":{"begin":607,"end":618},"obj":"Disease"},{"id":"111","span":{"begin":664,"end":680},"obj":"Disease"},{"id":"112","span":{"begin":742,"end":754},"obj":"Disease"},{"id":"113","span":{"begin":849,"end":858},"obj":"Disease"},{"id":"120","span":{"begin":1014,"end":1018},"obj":"Disease"},{"id":"121","span":{"begin":1021,"end":1058},"obj":"Disease"},{"id":"122","span":{"begin":1060,"end":1062},"obj":"Disease"},{"id":"123","span":{"begin":1065,"end":1082},"obj":"Disease"},{"id":"124","span":{"begin":1090,"end":1122},"obj":"Disease"},{"id":"125","span":{"begin":1213,"end":1222},"obj":"Disease"}],"attributes":[{"id":"A107","pred":"tao:has_database_id","subj":"107","obj":"Tax:9606"},{"id":"A108","pred":"tao:has_database_id","subj":"108","obj":"MESH:D029424"},{"id":"A109","pred":"tao:has_database_id","subj":"109","obj":"MESH:D009223"},{"id":"A110","pred":"tao:has_database_id","subj":"110","obj":"MESH:D009503"},{"id":"A111","pred":"tao:has_database_id","subj":"111","obj":"MESH:D007153"},{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"MESH:D006973"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"MESH:D003643"},{"id":"A120","pred":"tao:has_database_id","subj":"120","obj":"MESH:D029424"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"MESH:D029424"},{"id":"A122","pred":"tao:has_database_id","subj":"122","obj":"MESH:D009223"},{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"MESH:D003920"},{"id":"A124","pred":"tao:has_database_id","subj":"124","obj":"MESH:D055744"},{"id":"A125","pred":"tao:has_database_id","subj":"125","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 1. Characteristics of Included Patients\n IPA (n = 9) Non-IPA (n = 33) All Patients (N = 42)\nAge, yr, mean (range) 68 (39–76) 60 (25–79) 62 (25–79)\nSex, M, n (%) 5 (55.6%) 28 (84.8%) 33 (78.6%)\nBMI, kg/m2 30 [26–34] 27 [27–29] 29 [28–30]\nAPACHE IV pred mort 19% [12–25]* 21% [17–26] 21% [17–25]\nLowest PF ratio 94 [74–114] 102 [91–114] 100 [91.2–110.2]\nGalactomannan in BAL, ODI 3.33 [2.67–4.00]* 0.21 [0.17–0.27] 0.67 [0.39–0.95]\nCOPD, n (%) 4 (44.4%)* 4 (12.1%) 8 (19.0%)\nDM, n (%) 1 (11.1%) 9 (27.3%) 10 (23.8%)\nChronic corticosteroid use, n (%) 1 (11.1%) 0 1 (2.4%)\nNeutropenia, n 0 0 0\nStem cell transplant, n 0 0 0\nImmunodeficiency (acquired/inherited), n (%) 1 (11.1%) 0 1 (2.4%)\nArterial hypertension, n (%) 3 (33.3%) 10 (30.3%) 13 (30.9%)\nICU LOS, d 37 [26–47]* 19 [15–23] 23 [18–27]\nICU mortality, n (%) 2 (22.2%) 5 (15.1%) 7 (16.6%)\nDefinition of abbreviations: APACHE IV = Acute Physiology and Chronic Health Evaluation IV; BMI = body mass index; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; IPA = invasive pulmonary aspergillosis; LOS = length of stay; ODI = optical density index; PF = PaO2/FiO2; pred mort = predicted mortality.\nData are expressed as mean [95% confidence interval] unless stated otherwise.\n* P \u003c 0.05."}